Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

DoD Seeks Medical Countermeasure Manufacturing

by Global Biodefense Staff
June 6, 2016
Bioterrorism Vaccine Countermeasures

Bioterrorism Vaccine CountermeasuresThe U.S. Department of Defense (DoD) is conducting market research to identify vaccine developers who have advanced manufacturing platforms which are adaptable to incorporating known antigens for use as a prophylaxis countermeasure against weaponizable biological agents.

Manufacturers are sought with the capability to develop processes and deliver filled/finished material that is suitable to support non-clinical Investigational New Drug (IND)-enabling studies and for use in humans up through Phase 2 clinical trials under an IND application.

Specifically, the DoD is seeking information from manufacturers with a high level of control over their manufacturing platform processes and, at the appropriate time, the willingness to partner with the DoD to potentially transfer the manufacturing process to the DoD Advanced Development Manufacturing Capability (ADMC) facility, currently residing at Nanotherapeutics Inc in Alachua, Florida.

The DOD intends to use Eastern Equine Encephalitis virus (EEEV) as a test case, and will provide information and materials pertaining to the protective antigens, critical reagents for identity testing, non-clinical challenge models, immunogenicity assays and reagents, and challenge materials.

Further details are available via Solicitation Number: EEEV2016. The response deadline is June 30, 2016.

Tags: BioterrorismJPEO-CBRNDRFIVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC